Company intelligence / Profile preview

Ohr Pharmaceutical, Inc.

New York, New York, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

Squalamine in combination with Lucentis for wet AMD did not meet primary efficacy endpoint in January 2018. The company merged with NeuBase Therapeutics in 2019, with NeuBase stockholders becoming majority holders.

Therapeutic areas: OphthalmologyOncologyImmunologyNeurology
Modalities: Small moleculespeptide-nucleic acid (PNA) antisense oligonucleotide
Industry: Biotech

Drug pipeline

1 asset

squalamine lactate

Phase 3

Indications: Wet age-related macular degeneration

Partnerships

Cold Spring Harbor Laboratory

Beyond the preview

Go deeper on Ohr Pharmaceutical, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ohr Pharmaceutical, Inc..

Explore the full profile